Momelotinib for the treatment of myelofibrosis: real-world data

Dr Alexandros Rampotas is a haematologist at the UCL Cancer Institute in London (UK). During ASH 2024 he presented a poster with real-world data on the use of momelotinib in patients with myelofibrosis. The analysis included a total of 119 myelofibrosis patients who received momelotinib across 20 centers in the UK. The study confirmed that momelotinib effectively improves anemia, reduces the spleen volume and alleviates symptoms in a significant proportion of patients, both as a first- and second-line JAK inhibitor. Overall, the safety profile of momelotinib was in line with previous reports, although this analysis did reveal a higher-than-expected rate of thrombocytosis.